X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.onclive.com/view/cd38-48-upregulation-with-tazemetostat-may-overcome-daratumumab-resistance-in-multiple-myeloma
https://www.globenewswire.com//news-release/2023/09/12/2741225/0/en/HUTCHMED-Completes-Patient-Enrollment-of-a-Bridging-Study-of-Tazemetostat-in-Patients-with-Relapsed-Refractory-Follicular-Lymphoma-in-China.html
https://www.ipsen.com/press-releases/ipsen-completes-acquisition-of-epizyme-expanding-its-portfolio-in-oncology/
https://www.clinicaltrialsarena.com/news/hutchmed-follicular-lymphoma-therapy-trial/
https://www.fiercepharma.com/pharma/still-wheeling-and-dealing-ipsen-acquires-epizyme-and-lymphoma-drug-tazverik-247-million
https://www.globenewswire.com/news-release/2022/06/01/2453896/0/en/HUTCHMED-Announces-TAZVERIK-Approved-to-be-Used-in-Hainan-Pilot-Zone-in-China.html
https://www.fiercebiotech.com/biotech/epizyme-trim-its-workforce-and-reorganize-pipeline-it-looks-cut-costs
https://www.raps.org/news-and-articles/news-articles/2020/6/fda-round
https://www.biospace.com/article/releases/epizyme-to-present-data-from-tazemetostat-clinical-program-during-the-2020-asco-virtual-scientific-program/
https://endpts.com/astrazeneca-sweeps-two-cancer-drugs-to-the-scrap-heap-epizyme-nabs-priority-review-for-second-rare-cancer-nda/
https://www.prnewswire.com/news-releases/risdiplam-rg7916-pivotal-firefish-study-demonstrated-statistically-significant-improvement-in-infants-with-type-1-spinal-muscular-atrophy-300991624.html
https://endpts.com/fdas-in-house-review-offers-bleak-assessment-of-epizymes-tazemetostat-but-win-or-lose-this-cancer-drug-may-still-have-a-future/
https://endpts.com/fdas-in-house-review-offers-bleak-assessment-of-epizymes-tazemetostat-but-win-or-lose-this-cancer-drug-may-still-have-a-future/
https://www.businesswire.com/news/home/20191128005586/en/Results-Phase-III-SAkuraSky-Study-Chugai%E2%80%99s-Satralizumab/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.fiercebiotech.com/biotech/asco-fda-review-nearing-epizyme-shares-updated-sarcoma-data
https://www.businesswire.com/news/home/20190530005063/en/Epizyme-Submits-New-Drug-Application-U.S.-FDA/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.biopharmadive.com/news/epizyme-moves-forward-with-cancer-drug-eyes-2020-launch/555834/
https://www.businesswire.com/news/home/20181010005229/en/Epizyme-Present-Updated-Data-Tazemetostat-Full-Phase
https://www.xconomy.com/national/2018/09/28/bio-roundup-amarins-stunner-lung-cancer-news-data-dumps-more/
https://endpts.com/fda-gives-epizyme-a-green-light-on-trial-recruitment-but-tazemetostat-isnt-out-of-the-woods-yet/
https://www.fiercebiotech.com/biotech/fda-lifts-hold-epizyme-cancer-drug-shares-surge
https://endpts.com/epizyme-discards-a-failed-program-for-tazemetostat-as-execs-work-to-get-an-fda-hold-lifted/
https://www.genengnews.com/gen-news-highlights/epizyme-halts-phase-ii-trial-of-tazemetostat-in-dlbcl-continues-talks-to-lift-clinical-hold/81256092
https://www.fiercebiotech.com/biotech/epizyme-poaches-sqz-biotech-tesaro-biotech-vet-shefali-agarwal-as-cmo
https://www.fiercebiotech.com/biotech/fda-slaps-partial-hold-epizyme-s-lead-drug-analysts-say-don-t-panic
Market Place
Share 
